Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves First new type of pain medication in decades
FDA approves non-opioid pain medication dubbed possible medical ‘game changer’
The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr. Jianguo Cheng, from the Cleveland Clinic, constantly works with patients with acute pain.
FDA Approves the First Non-Opioid Pain Medicine in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.
Suzetrigine: First-in-Class Nonopioid Pain Therapy Is Approved by FDA
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.
17h
Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
Scientific American
3d
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
3d
Historic FDA approval marks first nonopioid breakthrough since Clinton era
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
Business Wire
4d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
About JOURNAVX™ (
suzetrigine
) JOURNAVX (
suzetrigine
) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels.
3h
on MSN
Can new drug promise pain relief without peril?
The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
FDA
Vertex
Journavx
Food and Drug Administration
pain
Feedback